Addyi vs generic: are they the same?
Addyi is the originator brand for the active ingredient Flibanserin. Once the original patent expired, authorised generic versions of the same active ingredient became available. For most users at 100mg, the practical question is: is the generic just as good, and what really differs?
What is the same
Authorised generics of Flibanserin contain the same active substance at the same 100mg strength as Addyi, with regulator-required bioequivalence to the originator. Clinical effect is, on average, the same. According to the prescribing information, generics meet the same regulatory standard and can substitute for the brand in most patients.
What can differ
Differences include manufacturer, country of production, excipients, tablet appearance, packaging and price. A small minority of patients react to a specific excipient that varies between manufacturers. Price is usually significantly lower for generics — often the most decisive practical difference for chronic use.
Frequently asked questions
Is generic Flibanserin as effective as Addyi? ▾
For most users at 100mg, yes — authorised generics of Flibanserin are required to demonstrate bioequivalence to Addyi and produce the same clinical effect on average. Some users notice no difference; a few report subjective differences that are usually due to excipients or expectation.
Why does Addyi cost more than the generic? ▾
The price difference reflects the originator's development costs, brand recognition and marketing, plus the larger volume and competition among generic manufacturers. The active ingredient Flibanserin itself is identical between brand and authorised generic at 100mg.
More on Addyi
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.